

## Pharmacy and Therapeutics Advisory Committee Recommendations

May 18, 2006 Meeting

This chart provides a summary of the final PDL selections that were made by the Secretary for Health and Family Services as a result of the Pharmacy and Therapeutics Advisory Committee meeting of May 18, 2006.

	Description of Recommendation	Final PDL Decision
#1	<b>Ophthalmic Antihistamines</b> <ol style="list-style-type: none"> <li>1. The ophthalmic antihistamines are considered to be equivalent in efficacy and safety.</li> <li>2. DMS to select at least 2 agents as preferred based on economic evaluation.</li> <li>3. Agents not selected as preferred based on economic evaluation will require PA.</li> <li>4. For any new chemical entity in the class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	Recommendations Approved  <u>PDL Selections</u> ELESTAT PATANOL
#2	<b>Ophthalmic Mast Cell Stabilizers</b> <ol style="list-style-type: none"> <li>1. The mast cell stabilizers are considered to be equivalent in efficacy and safety.</li> <li>2. DMS to select at least 2 agents as preferred based on economic evaluation.</li> <li>3. Agents not selected as preferred based on economic evaluation will require PA.</li> <li>4. For any new chemical entity in the class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	Recommendations Approved  <u>PDL Selections</u> ALOCRIL CROMOLYN SODIUM
#3	<b>Ophthalmic Quinolones</b> <ol style="list-style-type: none"> <li>1. The ophthalmic quinolones are considered to be equivalent in efficacy and safety.</li> <li>2. DMS to select agent(s) as preferred based on economic evaluation.</li> <li>3. Agents not selected as preferred based on economic evaluation will require PA.</li> <li>4. For any new chemical entity in the class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	Recommendations Approved  <u>PDL Selections</u> CIPROFLOXACIN HCL VIGAMOX
#4	<b>Alpha 2 Adrenergic Agents – Glaucoma</b> <ol style="list-style-type: none"> <li>1. The alpha 2 adrenergic agents for glaucoma are considered to be equivalent in efficacy and safety.</li> <li>2. DMS to select all agents as preferred.</li> <li>3. Agents to be reviewed in 1 year.</li> <li>4. For any new chemical entity in the class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	<u>PDL Selections</u> ALPHAGAN P BRIMONIDINE TARTRATE IOPIDINE
#5	<b>Beta Blockers Glaucoma</b> <ol style="list-style-type: none"> <li>1. The beta blockers for glaucoma are considered to be equivalent in efficacy and safety.</li> <li>2. DMS to select all agents as preferred.</li> <li>3. Agents to be reviewed in 1 year.</li> <li>4. For any new chemical entity in the class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	Recommendations Approved  <u>PDL Selections</u> BETAXOL HCL DROPS BETOPTIC S CARTEOLOL HCL ISTALOL LEVOBUNOLOL HCL METIPRANOLOL TIMOLOL MALEATE DROPS TIMOLOL MALEATE SOL- BETIMOL

## Pharmacy and Therapeutics Advisory Committee Recommendations

May 18, 2006 Meeting

#6	<b>Carbonic Anhydrase Inhibitors – Glaucoma</b> <ol style="list-style-type: none"> <li>1. The carbonic anhydrase inhibitors for glaucoma are considered to be equivalent in efficacy and safety.</li> <li>2. DMS to select all agents as preferred.</li> <li>3. Agents to be reviewed in 1 year.</li> <li>4. For any new chemical entity in the class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	Recommendations Approved  <u>PDL Selections</u> AZOPT COSOPT TRUSOPT
#7	<b>Ophthalmic Prostaglandin Agonists</b> <ol style="list-style-type: none"> <li>1. The prostaglandin agonists are considered to be equivalent in efficacy and safety.</li> <li>2. DMS to select all agents as preferred.</li> <li>3. Agents to be reviewed in 1 year.</li> <li>4. For any new chemical entity in the class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	Recommendations Approved  <u>PDL Selections</u> LUMIGAN TRAVATAN XALATAN
#8	<b>Ophthalmic NSAIDs</b> <ol style="list-style-type: none"> <li>1. The ophthalmic NSAIDs are considered to be equivalent in efficacy and safety.</li> <li>2. DMS to select agent(s) as preferred based on economic evaluation.</li> <li>3. Agents not selected as preferred based on economic evaluation will require PA.</li> <li>4. For any new chemical entity in the class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	Recommendations Approved  <u>PDL Selections</u> ACULAR ACULAR LS FLURBIPROFEN VOLTAREN DROPS
#9	<b>Otic Quinolones</b> <ol style="list-style-type: none"> <li>1. The otic quinolones are considered to be equivalent in efficacy and safety.</li> <li>2. DMS to select all agents as preferred.</li> <li>3. Agents to be reviewed in 1 year.</li> <li>4. For any new chemical entity in the class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	Recommendations Approved  <u>PDL Selections</u> CIPRO HC CIPRODEX FLOXIN DROPS